Key result
Higher serum elaidic acid levels were associated with the presence of thin-cap fibroatheroma (12.9 ± 4.9 vs. 10.3 ± 4.3 μmol/L, p=0.001) in patients with coronary artery disease.
Why the study?
Does higher serum trans fatty acid concentration increase plaque vulnerability in patients with coronary artery disease?
Observational (n=161)
Does higher serum trans fatty acid concentration increase plaque vulnerability in patients with coronary artery disease?
Higher serum trans fatty acid concentrations, specifically elaidic acid, are independently associated with increased plaque vulnerability (TCFA) in CAD patients despite guideline-directed medical therapy.
Answers are grounded in this paper and cite their sources.
Suggests a metabolic link to plaque vulnerability despite medical therapy; leaves open whether targeted dietary interventions can stabilize.
BACKGROUND AND AIMS: Recent epidemiological studies have showed that excessive intake of trans fatty acids (TFA) can be a residual risk for the development of coronary artery disease (CAD) even under medical management, including statins. This study aimed at investigating the association between lipid profile, including serum TFA concentration, and plaque vulnerability using optical coherence tomography (OCT). METHODS: The level of serum elaidic acid, a major TFA component, was measured using gas chromatography in 161 consecutively enrolled patients with CAD under guideline-directed risk factor management. OCT was performed to evaluate morphological features of angiographic intermediate stenosis (30% < diameter of stenosis <70%). OCT data were also used to measure lipid index (LI), defined as mean lipid arc multiplied by lipid length, and determine the presence of thin-cap fibroatheroma (TCFA), defined as a lipid-rich plaque with the smallest fibrous cap thickness <65 μm and the maximal arc >90°. RESULTS: Among 190 lesions assessed using OCT, 49 TCFAs were detected. In patients with at least one TCFA lesion, levels of elaidic acid (12.9 ± 4.9 vs. 10.3 ± 4.3 μmol/L, p = 0.001), triglycerides (169 ± 81 vs. 130 ± 60 mg/dL, p = 0.005), and remnant-like particle cholesterol (10.4 ± 6.5 vs. 7.7 ± 4.7 mg/dL, p = 0.005) were higher than in those without TCFAs. Generalized estimating equations identified elaidic acid level as the independent risk factor of TCFA. LI had a positive correlation with elaidic acid level (r = 0.173, p = 0.025). CONCLUSIONS: TFA may affect plaque vulnerability in patients with CAD. Serum TFA concentration may represent another cardiovascular risk factor during conventional risk factor management.
No takes yet. Share an insight, caveat, or question.
Nagasawa et al. (2017) conducted an observational in Coronary artery disease (n=161). Serum trans fatty acids (elaidic acid) concentration vs. Lower serum trans fatty acids concentration was evaluated on Presence of thin-cap fibroatheroma (TCFA) (p=0.001). Higher serum elaidic acid levels were associated with the presence of thin-cap fibroatheroma (12.9 ± 4.9 vs. 10.3 ± 4.3 μmol/L, p=0.001) in patients with coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: